Additional Information

Overview
This monograph reviews new data on maintenance and early second-line therapies in the treatment of non-small cell lung cancer (NSCLC) and discussion of 3 cases by five experts in the field.  Non-small cell lung cancer has long been treated with first-line platinum-based chemotherapy for 4 to 6 cycles followed by a break, then second-line treatment upon progression. The approaches discussed challenge the current paradigm: (1) early second-line chemotherapy and (2) adding targeted antibodies to the chemotherapy followed by a maintenance antibody phase of treatment.

Learning Objectives

• Discuss the rationale for early second-line treatment of non–small cell lung cancer (NSCLC).
• Discuss advantages and disadvantages of maintenance antibody therapy in NSCLC.
• Assess treatment strategies incorporating early second-line and/ or maintenance protocols for individual patients.
• Assess implications of data on early second-line and maintenance protocols for practice change.

The CME activity has expired.  See links below to view the monograph.

Program Faculty
Thomas J. Lynch, Jr., MD
Director, Yale Cancer Center
Physician-in-Chief, Smilow Cancer Center at Yale
New Haven, Connecticut

Alan B. Sandler, MD
Division Chief, Hematology/Oncology
Oregon Health and Science University
Portland, Oregon

Panos Fidias, MD
Clinical Director, Center for Thoracic Cancers
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Nasser H. Hanna, MD
Division of Hematology/Oncology
Indiana University School of Medicine
Indianapolis, Indiana

Shadia Jalal, MD
Division of Hematology/Oncology
Indiana University School of Medicine
Indianapolis, Indiana

Target Audience
Medical, surgical, and radiation oncologists and other medical professionals who assess, treat, and counsel patients with lung cancer.

Educational Grant Support
Supported by educational grants provided by: Genentech BioOncology and OSI Oncology, and sanofi-aventis, U.S.

Sponsorship
CME sponsorship and program management provided by InforMEDical Communications, Inc.

The CME activity has expired.